Anti-btn3a antibodies and their use in treating cancer or infectious disorders
AssigneesImcheck Therapeutics SAS, Inserm (Institut National De La Sante Et De La Recherche Medicale), Université Aix-Marseille, Institut Jean Paoli & Irene Calmette, Centre National de la Recherche Scientifique (CNRS)
InventorsAlemseged TRUNEH, Daniel OLIVE, Christine PASERO, Aude DE GASSART
Life of this patent
Estimating the term…
Abstract
The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
Claims10
A pharmaceutical composition comprising an anti-BTN3A antibody and a pharmaceutically acceptable carrier, wherein the anti-BTN3A antibody comprises a variable heavy chain polypeptide VH of SEQ ID NO:1 and a variable light chain polypeptide VL of SEQ ID NO:2.
Dependencies are inferred from the claim text.